^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug Class: | HER2 inhibitor + Erythropoiesis stimulating agent |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
Published date:
11/08/2023
Excerpt:
In total, 1506 (18.0%) DFS events were observed, with 3- and 7-year DFS rate estimates in the entire population equal to 88.3% (95% CI 87.6–89.0%) and 80.1% (95% CI 79.1–81.0%), respectively….In summary, our study concludes that ESA administration to patients receiving adjuvant anti-HER2 treatment for HER2-positive EBC in the ALTTO trial was safe and had no detrimental impact on survival outcomes.
DOI:
10.1007/s10549-023-07159-9
Trial ID: